404
Budesonide Market Report
Budesonide Market, Dynamics, Trends, Market Insights
The report on the Budesonide Market is segmented By Type (Injectable Suspension, Aerosols, Inhalation Powder, Tablet & Capsule), By Application (Respiratory Disease Treatment, Nose Disease Treatment, Inflammatory Bowel Disease Treatment, Others), and Region. This report also covers COVID-19 Impact Analysis and Forecast to 2026.This market research report provides an in-depth information on trends, dynamics, revenue opportunities, competitive landscape, and recent developments in the global budesonide market. The historic years considered for the study are 2016-2019, the base year is 2020, the estimated year is 2021, and the forecast period is 2022-2026.
AstraZeneca (UK), Teva (Israel), Mylan (The U.S), Sandoz (Switzerland), Cosmo Pharmaceuticals (Ireland), Salix (The U.S), Chiesi Farmaceutici (Italy), Orion Corporation (Finland), Cipla (India) and Synmosa Biopharma (Taiwan) are among the key players in the budesonide market.
Asia Pacific market accounted for the largest share in 2020 and is expected to grow at a substantial CAGR.
China is expected to dominate the budesonide market in Asia-pacific region in the coming years.
The respiratory disease treatment segment is expected to grow at the highest CAGR in the budesonide market during the forecast period.
The rising prevalence of asthma around the globe, strong growth in healthcare infrastructure, the surge in the diagnosis and treatment rate of asthma, and favourable reimbursement policies are the factors driving the growth of budesonide market.
Budesonide vendors, Budesonide retailers, Pharmaceutical companies, Hospitals are the target audience in the budesonide market.